Ultragenyx Pharmaceutical (RARE) Intangibles (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Intangibles data on file, last reported at $174.0 million in Q1 2026.

• On a quarterly basis, Intangibles fell 1.43% year-over-year to $174.0 million in Q1 2026; TTM through Mar 2026 was $174.0 million, a 1.43% decrease from a year earlier, with the FY2025 full-year figure at $176.0 million, down 1.12% from the prior year.
• Intangibles for Q1 2026 stood at $174.0 million, down from $176.0 million in the prior quarter.
• Over the last five years, Intangibles for RARE reached as high as $178.0 million in Q4 2024 and fell as low as $157.3 million in Q3 2023.
• Historically, Intangibles has averaged $166.7 million across 5 years, with a median of $165.0 million in 2024.
• Across the five-year window, Intangibles advanced 22.42% in 2022 and retreated 1.43% in 2026, its largest moves.
• Year by year, Intangibles stood at $160.1 million in 2022, then increased by 8.54% to $173.8 million in 2023, then rose by 2.43% to $178.0 million in 2024, then retreated by 1.12% to $176.0 million in 2025, then decreased by 1.14% to $174.0 million in 2026.
• Per Business Quant data, the three most recent Intangibles figures were $174.0 million in Q1 2026, $176.0 million in Q4 2025, and $172.9 million in Q3 2025.